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Abstract: Most histone methyltransferases (HMTase) harbor a predicted Su(var)3–9, Enhancer-of-zeste,
Trithorax (SET) domain, which transfers a methyl group to a lysine residue in their substrates.
Mutations of the SET domains were reported to cause intellectual disability syndromes such as Sotos,
Weaver, or Kabuki syndromes. Sotos syndrome is an overgrowth syndrome with intellectual disability
caused by haploinsufficiency of the nuclear receptor binding SET domain protein 1 (NSD1) gene,
an HMTase at 5q35.2–35.3. Here, we analyzed NSD1 in 34 Brazilian Sotos patients and identified
three novel and eight known mutations. Using protein modeling and bioinformatic approaches, we
evaluated the effects of one novel (I2007F) and 21 previously reported missense mutations in the
SET domain. For the I2007F mutation, we observed conformational change and loss of structural
stability in Molecular Dynamics (MD) simulations which may lead to loss-of-function of the SET
domain. For six mutations near the ligand-binding site we observed in simulations steric clashes with
neighboring side chains near the substrate S-Adenosyl methionine (SAM) binding site, which may
disrupt the enzymatic activity of NSD1. These results point to a structural mechanism underlying the
pathology of the NSD1 missense mutations in the SET domain in Sotos syndrome. NSD1 mutations
were identified in only 32% of the Brazilian Sotos patients in our study cohort suggesting other genes
(including unknown disease genes) underlie the molecular etiology for the majority of these patients.
Our studies also found NSD1 expression to be profound in human fetal brain and cerebellum,
accounting for prenatal onset and hypoplasia of cerebellar vermis seen in Sotos syndrome.
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1. Introduction
Sotos syndrome (MIM 117550), also known as cerebral gigantism with intellectual disability and
delayed development of motor skills, was initially described in 1964, and hundreds of cases have been
subsequently reported [1–5]. Most reported cases have been sporadic, but occasional familial cases
have demonstrated that Sotos syndrome is also autosomal dominant [6,7]. Because of the phenotypic
overlap, Sotos syndrome is sometimes difficult to distinguish from several other clinical disorders
such as Weaver syndrome (MIM 277590), Bannayan–Riley–Ruvalcaba syndrome (MIM 153480) and
Beckwith–Wiedemann syndrome (MIM 130650) [8]. Therefore, identification of a causative gene was
necessary for the precise genetic diagnosis and understanding of the molecular and physiological basis
of Sotos syndrome.
In 2002, positional cloning in a Sotos syndrome individual with a balanced translocation,
t(5;8)(q35;q24.1), resulted in the identification of a nuclear receptor binding SET domain protein
1 (NSD1) located at the 5q35 breakpoint as a causative gene, and early studies have shown that
haploinsufficiency of NSD1 is the underlying cause of this syndrome [9,10]. To date, over 400 different
mutations in NSD1 associated with Sotos syndrome have been reported. Various mutations abrogating
NSD1 function include missense mutations, partial gene deletions, microdeletions and truncating
mutations resulting from small nucleotide insertions, deletions or splice-site mutations [3,4,11,12].
More than 80% of patients with Sotos syndrome carry NSD1 mutations, whereas for 20% of
phenotypically characterized cases with Sotos syndrome underlying aberrations in the NSD1 gene
have not been detected [5,13]. In particular, partial or whole NSD1 gene 5q35 microdeletions are the
most common cause of Sotos syndrome in Japanese patients. In non-Japanese patients, however, 5q35
microdeletions are uncommon, accounting for only 10% of affected individuals [4,11,14,15].
NSD1 encodes a protein containing multiple functional domains including an SET [Su(var)3–9,
Enhancer-of-zeste, Trithorax] domain, which is required for histone methyltransferase (HMTase)
activity and thus present in most HMTases [16–18]. NSD1 also apparently contains five zinc finger-like
plant homeodomain (PHD) domains and two proline-tryptophan-tryptophan-proline (PWWP) motifs,
both of which are involved in protein–protein interactions [19,20]. However, the number of functional
domains in NSD1, especially the PHD domain, has not been clearly defined yet [13,19,21,22]. NSD1
is a member of mammalian histone lysine methyltransferases that play important roles in multiple
aspects of development and disease by acting as a transcriptional intermediary factor capable of both
negatively and positively influencing transcription of nuclear receptors, such as the estrogen, retinoic
acid and thyroid hormone receptors, depending on the cellular context [22–25].
Most NSD1 missense mutations are present in the functional domains of NSD1, and to date a
total of 21 missense mutations have been identified in the SET domain [4,5,11,13,26–29]. Although the
SET domain has a crucial role in NSD1 function, the mechanisms by which these mutations result in
loss-of-function have been poorly understood. In this study, we performed a systematic screening
for NSD1 mutations to evaluate the range and contribution of different NSD1 aberrations to the
spectrum of associated clinical features in Brazilian Sotos patients. In addition, using protein modeling
and bioinformatic approaches, we investigated the impact of all reported missense mutations in the
SET domain of the NSD1 protein. This study suggests that mutations in the SET domain of NSD1
may disrupt its HMTase activity by changing protein stability and interfering with its ability to bind
a ligand.
2. Materials and Methods
2.1. Patients
A total of 34 Brazilian patients with Sotos syndrome were analyzed in this study. Each patient
had been examined by a clinical geneticist or experienced pediatrician and satisfied strict criteria for a
diagnosis of Sotos syndrome including facial features, macrosomia and neurological findings. We also
checked the internal whole exome sequencing database of 600 healthy Brazilian controls to confirm
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that the mutations we found are not polymorphisms. For the screening of familial inheritance, parental
and sibling DNA samples from seven families were also analyzed to see whether the novel mutations
in four patients are de novo or inherited. Written informed consent forms were obtained from all
involved patients. This study was approved by the Institutional Review Board of Augusta University
and Hospital das Clínicas-São Paulo (CAPPesq number 0371/2010).
2.2. Genomic DNA Extraction
Genomic DNA was isolated from peripheral blood lymphocytes by standard methods of
phenol/chloroform extraction and ethanol precipitation [30].
2.3. NSD1 Mutation Analysis
For each patient, exons 2 through 23 of the NSD1 gene were amplified by polymerase chain
reaction (PCR) using approximately 100 ng of genomic DNA and 2×AmpliTaq Gold® PCR Mastermix
(Life Technologies, Carlsbad, CA, USA) in a 25 µL reaction volume. PCR conditions were as follows:
94 ◦C for 4 min; 35 cycles of 94 ◦C for 30 s, 62 ◦C for 30 s, and 72 ◦C for 45 s; 72 ◦C for 5 min. Primer
sequences are listed in Table S1 in Supplementary Materials. PCR products were purified using USB®
ExoSAP-IT® reagent (Affymetrix, Santa Clara, CA, USA) following the manufacturer’s protocol, and
sequenced using M13 primers and BigDye® Terminator chemistry version 3.1 (Life Technologies)
in a 10 µL reaction volume. DNA sequencing reaction conditions were as follows: 96 ◦C for 1 min;
25 cycles of 96 ◦C for 10 s, 50 ◦C for 5 s, and 60 ◦C for 1 min 15 s. Each product was then purified using
either the Agencourt® CleanSEQ® dye terminator removal protocol on a Biomek® FXP workstation
(Beckman Coulter, Brea, CA, USA) or the EdgeBio Performa® DTR V3 96-Well Short Plates method
of dye terminator removal. Products were sequenced by the Sanger dideoxynucleotide method
using an Applied Biosystems 3730XL DNA Analyzer instrument (Life Technologies). Sequence reads
were aligned to reference sequence NM_022455.4 and analyzed for DNA sequence changes using
Sequencher® software version 4.9 DNA analysis software (Gene Codes Corporation, AnnArbor, MI,
USA) and Sequence Pilot version 4.2.2 (JSI Medical Systems, Ettenheim, Germany) software. Any
identified sequence alterations were queried against the Single Nucleotide Polymorphism database
(dbSNP; NCBI; http://www.ncbi.nlm.nih.gov/SNP/) and the Human Gene Mutation Database
(HGMD® Professional; BIOBASE Biological Databases; https://portal.biobase-international.com).
2.4. Reverse Transcription-quantitative PCR (RT-qPCR)
Primers targeting NSD1 exons 5 were designed for RT-qPCR (Table S2. Total RNA from whole
human brain, fetal brain and from an additional 11 different central nervous system (CNS) regions
(Clontech, Mountain View, CA, USA) were used to investigate NSD1 transcripts levels. Complementary
DNA (cDNA) was synthesized from 1 µg of total RNA using the RevertAid First cDNA Synthesis
Kit (Thermo Scientific, Waltham, MA, USA). RT-qPCR assays were performed using 2 µL cDNA,
2.5 µM primer and 10 µL FastStart DNA Green Master (Roche, Indianapolis, IN, USA) in a 20 µL
reaction volume.
2.5. Protein Modeling and Bioinformatics Analysis
Molecular Dynamics (MD) simulations were carried out using the program package GROMACS
4.5.4. [31]. The force field OPLS-AA [32] was used in all MD simulations. The crystal structure of
the native SET domain (PDB ID: 3OOI) and the I2007F model (generated using MOE (Molecular
Operating Environment, 2013.08; Chemical Computing Group Inc., Montreal, QC, Canada) without
S-Adenosyl methionine (SAM) and histone peptide were used as a starting point for MD simulations.
The native and mutant proteins were solvated with Simple Point Charge (SPC) water molecules [33].
Periodic boundary conditions were applied in an isothermal–isobaric (NPT) ensemble simulation.
The system was neutralized by adding sodium ions and the temperature was controlled using a
Berendsen thermostat [34] with a coupling time of 0.2 ps. The minimized system was equilibrated
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for 1000 ps each at 300 K in a position restrained molecular dynamics simulation in order to solvate
the proteins. The equilibrated systems were then subjected to molecular dynamics simulations for
150 ns each at 300 K. From the trajectory we computed the distance between selected amino acids,
which we plotted using the GRaphing, Advanced Computation and Exploration (GRACE) program
(http://plasma-gate.weizmann.ac.il/Grace).
Some information regarding the effect of point mutations on the NSD1 protein function could
already be obtained at the sequence level using in silico approaches. We used in silico tools including
I-Mutant 2.0 [35], SPPIDER [36], Polyphen [37], PANTHER [38] and SIFT [39] (on all the mutations
in Table 4) to calculate the relative residue stability constants for the wild-type (WT) protein and
its mutant forms. These methods are trained on existing sets of mutations/phenotype association
data and use sequence homologs, structural information, such as solvent accessible surface area and
changes in amino acid properties, to provide information as input to machine learning methods for
phenotype prediction.
3. Results
We first investigated the domain structure of NSD1 using bioinformatic approaches. The NSD1
gene encodes a protein containing three PHD domains at amino acid positions 1543–1589, 1707–1751
and 2120–2160, predicted with high confidence using Pfam [40] and National Center for Biotechnology
Information Basic Local Alignment Search tool (NCBI–BLAST) [41]. The SMART [42] server also
predicts putative PHD domains at positions 1590–1639 and 1640–1693. However, a putative
PHD domain at position 2164–2205 reported previously [19] was not found with this approach.
The bioinformatics approach confirmed the existence of other domains, including one SET domain
at amino acid position 1942–2065, two PWWP domains at positions 323–388 and 1756–1818, one
associated with SET (AWS) domain at position 1890–1940 and one Post–SET domain at position
2066–2082, as previously reported (Figure 1A,B and Table 1) [19]. Three nuclear localization signals
(NLSs) are located at amino acid positions 512–529, 1157–1174 and 1471–1488 [21].
Assaying the expression levels of NSD1 mRNA in various regions of the brain by RT-qPCR
revealed that the gene is highly expressed throughout the brain. Approximately 60-fold higher
expression was detected in the cerebellum, while ~30-fold higher transcript levels were recorded in
the insula, parietal lobe and hippocampus compared to lymphocytes. Fetal brain showed ~75-fold
higher transcript levels relative to lymphocytes. The lowest levels of NSD1 transcripts were detected
in the dorsal root ganglion and spinal cord (Figure 2).
Table 1. Locations of functional domains in NSD1.
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Genomic DNAs samples from 34 Brazilian patients with phenotypes of Sotos or Sotos-like
syndrome as well as DNA samples from unaffected members of seven unrelated families were screened
for intragenic NSD1 mutations by Sanger sequencing analysis. We identified NSD1 mutations in 11
out of 34 patients, including three novel mutations (Table 2). In our patient DGDP186, one novel
nonsense mutation (c.5004C>A; NM_022455.4) was identified in exon 14 resulting in the substitution
of a tyrosine by a premature stop codon TAA at amino acid position 1668 in the third PHD domain
(p.Y1668X; NP_071900.2, Figure 1A, Table 2). This substitution results in the premature truncation of
the NSD1 protein with the deletion of C-terminal functional domains of NSD1 including the PWWP2,
AWS, SET and PHD domains 3–5 (Figure 1B). Parental DNA analysis demonstrated that the c.5004C>A
(p.Y1668X) mutation in this patient is de novo.
Table 2. Clinical features in Brazilian Sotos patients with novel NSD1 mutations.
Patient DGDP186 (Male) DGDP 291 (Female) DGDP306 (Female)
Age at diagnosis 9 months 2 years 7 months 1 year 5 months
Current age 10 years 23 year 5 years
Nucleotide change
(NM_022455.4) c.5004C>A c.6019A>T c.2699delC
Exon 14 20 5
Amino acid change
(NP_071900.2) p.Y1668X p.I2007F p.P900LfsX12
Familial analysis de novo Both mother and brother withno variant, father unavailable de novo
Brazilian control analysis not found in 600 controls not found in 600 controls not found in 600 controls
Developmental Milestone
Prenatal overgrowth − − −
Excessive growth velocity + + +
Advanced bone age − + +
Large hands and feet + + +
Developmental delay Mild Mild Mild
Lack of fine motor control − − −
Walking at 22 months 24 months 23 months
Speaking Delayed Delayed Delayed
Delayed learning ability − + N/A
Facial Dysmorphism
Macrocephaly + + +
Prominent forehead + + +
High-arched palate + − +
Pointed chin + + +
Other Features
Hypotonia + + +
Seizures − − +
Scoliosis + + −
Enlarged ventricles + N/A +
Artrial septal defect − + −
Pulmonary stenosis − + −
N/A, not applicable.
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One missense mutation (c.6019A>T, p.I2007F) was identified in patient DGDP291 (Figure 1A,
Table 2). This alteration occurs within the highly conserved SET domain (Figure 1B), where it may
have critical effects on the histone methyltransferase activity of NSD1. Paternal DNA was unavailable
for analysis; however, the familial genetic analysis including the healthy mother and unaffected
brother revealed that this mutation was likely de novo, and this mutation was not present in the other
34 patients or the more than 600 Brazilian control individuals. This change is also not present in the
Exome Aggregation Consortium (ExAC) database [43]. Analysis of its position within NSD1 provides
further evidence supporting a pathogenic role for this missense mutation. This alteration occurs at
amino acid residue 2007 within the functional domain that is conserved not only in other species such
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Figure 3. Multiple amino acid seq e ce ali e t of S 1 vertebrate orthologs and paralogs, in
which I2007 shows a full invariant conservation. ( ) lign ent of NSD1 orthologs from the Gallus
gallus, Mus musculus and Rattus norvegicus. ino acid residues surrounding p.I2007 in vertebrate
orthologs are evolutionarily fully conserved, suggesting the functional importance of the SET domain;
(B) Alignment of human NSD1, NSD2 and NSD3. Amino acid sequence alignment of NSD1 paralogs
show partial consensus, indicating their differential functions.
In another patient, DGDP306, a one base-pair deletion in exon 5 of the NSD1 gene (c.2699delC)
was identified which leads to a frameshift mutation resulting in the premature termination of protein
translation at amino acid 911 (p.P900LfsX12; Figure 1A, Table 2). The remaining protein fragment
contains only the N-terminal region of the NSD1 protein, including one functional PWWP domain
(Figure 1B). This may lead to loss-of-function of the protein causing Soto syndrome. Analysis of
parental samples indicated that the mutation had ccurred de novo. Since two f the novel mutations
we e predicted to result in premat re truncation of the NSD1 protein be ause of either nonsense or
frameshift mutations, these two mutations are considered to be pathogenic.
Additionally, eight previously-reported mutations including thr e frameshift mutations
(p.S985CfsX25 [13], p.K1002EfsX8 [44] and p.K1580NfsX62 [45]), two nonsense mutations (p.R632X [1]
and p.Q1989X [4]), one splice-site mutation (c.5892+1G>T, exon 19 skipping [5]) and two issense
mutations (p.L1917P [46] and p.R2017Q [11]) were identified in our Sotos patients. Among them,
two mutations, c.4740delA and c.5892+1G>T, were de novo in patients DGDP173 and DGDP176,
respectively, whose parental samples were available. The nomenclature of the previously reported
frameshift mutation p.K1002GfsX8 [44] has been corrected herein to p.K1002EfsX8. We also observed
16 polymorphisms (Table S3). These were considered nonpathogenic, since they were already identified
in multiple individuals including those in healthy populations. Since exons 5 (2560 bp) and 23 (1628 bp
without 3’-untranslated region (UTR)) are very large, a number of polymorphisms have been identified
in these two exons. The polymorphisms we identified in our patients were also located only in exons
5 and 23, except for one single nucleotide polymorphism (SNP) rs79098301 in intron 17 (Table S2).
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Interestingly, one synonymous polymorphism rs28580074 in exon 23 (c.6829T>C, p.L2277L) was
observed in all of our 34 Sotos patients, of which 26 patients were homozygous for this change.
The clinical features of the patients with novel mutations are summarized in Table 2. Our patient
DGDP186 with a novel nonsense mutation has a typical facial gestalt in association with a
variable number of additional major criteria including overgrowth, developmental delay and facial
dysmorphism (Figure 4A,B). Although this patient did not show advanced bone age, one of the major
diagnostic criteria for Sotos syndrome, his other phenotypic features satisfy other major diagnostic
criteria such as macrocephaly, post-natal overgrowth and delayed milestones. Another patient
DGDP306 with a novel frameshift mutation also has the typical facial dysmorphisms observed in other
Sotos patients. The neurologic involvement seems to be predominant in this patient characterized
by hypotonia, seizures and increased subarachnoid spaces. This girl had a markedly advanced bone
age (her bone age was three years six months at one year eight months of age). This patient shows
excessive growth velocity compared to other control populations at the same age. In addition, her
developmental milestones are delayed. The third Sotos patient DGDP291 with a novel NSD1 mutation
also shows a typical Sotos phenotype including post-natal overgrowth, developmental delay and facial
gestalt (Figure 4C,D). She has advanced bone age and macrocephaly as well as delayed learning ability.
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Table 3. Clinical features in Brazilian Sotos patients with known NSD1 mutations.
Patient DGDP168 DGDP171 DGDP173 DGDP174 DGDP176 DGDP180 DGDP183 DGDP305
Age at diagnosis 7 years 14 years 3 months 8 years 3 months 9 months 1 years 6 months 1 years 9 months 7 years 2 years 8 months
Current age 25 years 27 years 18 years 13 years 20 years 15 years 18 years 7 years
Nucleotide change (NM_022455.4) 3004_3005 delAA 5750T>A 4740delA 6050G>A 5892+1G>T 2954_2955 delCT 1894C>T 5965C>T
Exon or intron 5 18 12 20 Intron 19 5 5 19
Amino acid change (NP_071900.2) p.K1002EfsX8 p.L1917P p.K1580NfsX62 p.R2017Q Exon 19 skipping p.S985CfsX25 p.R632X p.Q1989X
Developmental Milestone
Prenatal overgrowth + + + − + − − +
Excessive growth velocity + + + − + + + +
Advanced bone age − + + + + + − +
Large hands and feet + + + + + + + +
Developmental delay Mild Mild Mild Mild Mild Mild Mild Mild
Lack of fine motor control − + + + + + − +
Walking at 15 months 24 months 18 months 20 months 17 months 20 months Delayed 20 months
Speaking Delayed Delayed Normal Delayed Delayed Delayed Delayed Normal
Delayed learning ability + + + + + + + +
Facial Dysmorphism
Macrocephaly + + + − + + + +
Prominent forehead + + + + + + + +
High-arched palate − + + + + + + +
Pointed chin + + + + + + + +
Other features
Hypotonia + + + + + + + +
Seizures − − − − − − + −
Scoliosis − − − − + + − +
Enlarged ventricles + + + + + − − −
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To explore the effect of I2007F point mutation in the SET domain of the protein encoded by
NSD1, we generated a mutant structural model using sequence alignment (ClustalW) [47] based on the
homology to the human histone-lysine N-methyltransferase NSD1 SET domain (PDB ID: 3OOI) [48]
(116 amino acids; spanning the amino acid sequence 1942–2063) as template protein. Figure 5A shows
the model for the SET domain which is composed of three β-sheets (yellow) arranged in a triangular
fashion and one long helix (red) exposed to the outside. The novel mutation p.I2007F is predicted to
be non-tolerable using SIFT server [39,49–52] and is predicted to decrease the stability of the protein
with a negative DDG (delta delta G/free energy change) value of −1.65. This mutation is located in
the evolutionarily fully conserved SET domain, with both WT and mutant residues interacting with
surrounding amino acids. Mutation of this invariant residue to phenylalanine likely causes steric
clashes with neighboring side chains, as phenylalanine is bulkier than isoleucine, and can affect the
SAM ligand-binding pocket. To verify this assumption, we performed MD simulations on the wild
type SET domain of the NSD1 protein and the protein with the p.I2007F alteration to predict the
conformational change induced by the mutation in and around the ligand binding site. Figure 5B
(black line) illustrates the distance D1 between native p.R1952 and p.I1993 residues in the ligand
binding pocket and Figure 5C (black line) illustrates the distance D2 between native p.D2002 and
p.T2038 residues around the ligand-binding pocket. The WT protein maintains a distance in the
range of 10.3–16.9 Å for D1 (D1 (average) = 10.48 ± 1.88 Å) and distance in the range of 10.8–15.3 Å
(D2 (average) = 12.60 ± 0.82 Å) for D2. We also measured the distances between these positions in the
crystal structure of the human histone-lysine N-methyltransferase NSD1 SET domain (PDB ID: 3OOI)
which was D1 = 13.8 Å and D2 = 8.2 Å. In the p.I2007F mutant the distance D1 shrinks to a range of
3.4–13.7 Å (D1 (average) = 9.79 ± 1.97 Å) and the D2 to a range of 3–7 Å (D2 (average) = 6.67 ± 1.22 Å).
Substitution of isoleucine to phenylalanine reduces the size of the binding pocket that can strongly
affect the ligand/histone peptide-binding properties. We also performed principal component analysis
(PCA) on the trajectories. The PCA scatter plot for the WT and I2007F mutant in Figure 6A,B shows
a significant difference in the motion of both systems as evident from the characteristic structures
plotted along the direction of two principal components. From the PCA scatter plot it is clear that the
eigenvectors computed from the MD trajectories for both the systems, the WT and p.I2007F mutant
(Figure 6), differ significantly. This indicates the difference in protein motion between the WT and the
mutant protein. The most pronounced flexibility observed in the WT protein was around residues
I2007–M2020 (loop), which flips the residues K2013 and Y2016 towards the SAM binding pocket.
The residues R2018 and M2020 in this loop region are known to interact with K20 of H4 peptide
through hydrogen bonding [53] thus stabilizing the complex. A similar conserved hydrogen bonding
is observed amongst all lysine-HMTases (H4K20-SETD8, H3K4-SETD7, H3K27-vSET, GLP and Dim-5).
However, this motion is not observed in the pI2007F mutant, the significant structural motion observed
in the mutant occurs in the vicinity of the K2031-G2041 loop. This is also supported by the difference
in the distance between residues D2003–T2038 in the Figure 5C. From the analysis on WT and I2007F
mutant, it is clear that the p.I2007F mutation causes changes in the conformational state of the protein
and the motion observed during the simulation, suggest change in and around the binding pocket
in the mutant state (closed state) as compared to the open state in WT protein. It is likely that the
loop flipping around residues I2007–R2017 (loop) might participate in the H4 peptide binding to the
SET domain. However, in our simulations, the SAM co-factor and H4 peptide are not included in the
complex, so these interactions are not possible to observe.
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Figure 5. Inhibitory effect of the novel mutation, p.I2007F on ligand-binding properties. (A) Structural
model for the human NSD1 SET domain protein (1946–2063 amino acids) in complex with S-Adenosyl
methionine (SAM) (PDB ID: 3OOI). Color code: red indicates helix; yellow specifies strands; green
signifies loops; and blue represents positions of the missense mutation sites including our novel
mutation p.I2007F in Table 4. Residues p.R1952, p.Y1997, p.R2017, p.N2020, and p.H2021 interact
with SAM, which is bound in a pocket formed by the SET domain. The SAM binding site is also
labeled. Six mutations (p.I2007F, p.R2017Q, p.R2017W, p.H2021R, p.C2027R and p.G2041D) which
might cause steric clashes with neighboring amino acid side chains are also shown in blue and
underlined; (B,C) Molecular Dynamics (MD) Trajectory analysis of the wild-type (WT) (in black)
and p.I2007F mutant (in red); where X-axis is the length of the simulation in nanoseconds (ns) and
Y-axis is the distance in nano-meter (nm); (B) Distance D1 between residues p.R1952 and p.I1993
in the ligand-binding site for native type (black line) and mutant model (red line). Substitution
of phenylalanine shrinks the distance D1 from a range of 10.3–16.9 Å (D1 = 10.48 ± 1.88 Å) to a
range of 3.4–13.7 Å (D1 = 9.79 ± 1.97 Å); (C) Distance D2 between residues p.D2002 and p.T2038
in the ligand-binding site for native type (black line) and mutant model (red line). Substitution
of phenylalanine shrinks the distance D2 from a range of 10.8–15.3 Å (D2 = 12.60 ± 0.82 Å) to a
range of 3.0–7.0 Å (D2 = 6.67 ± 1.22 Å). Therefore, the mutation from isoleucine to phenylalanine
at amino acid position 2007 significantly reduces the size of the binding pocket that strongly affects
ligand-binding properties.
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Figure 6. PCA scatter plot along first two principal components, PC1 and PC2 of WT and I2007F
mutant. (A) Show the differences in the motion between wild type (in black) and I2007F mutant (in red)
over the simulation time; (B) Projection of the eigenvectors (vectors 1 and 2) along Y-axis and time on
X-axis (in picoseconds; ps).
A nu ber of point mutations have been previously reported in the SET domain, including
p.R1952W, p.G1955D, p.Y1997S, p.C2027R, p.G2041D, p.Y2058C [4], p.I1962T, p.R1984G [26], p.R1984Q,
p.Y1997C, p.R2017W [27], p.Y1997H, .N2020S [13], p.R2005Q, . 2017 [11], p.A2009V, .H2021R,
p.C2027Y, p.W2032L [5], p.R2039C [29] and p.T2055I [28]. Figure 5A shows the positions of the
point mutations in the SET domain model. We performed a bioinformatics-based analysis using
SPPIDER [36], PolyPhen2 [37] and SIFT [49] on the effect of all of these mutations (Table 4). We also
used the HMM based evolutionary approach PANTHER to investigate the impact of point mutations
on protein functi n [38]. Using the HMM based evolutionary appr ach, 18 out of 22 point mutati ns
were designated as deleterious with subPSEC (substitution position-specific ev lutionary conservation)
sc res in the range of −9.24 to −3.04. Four ther mutations exhibited a subPSEC score in the range
of −1.96 to −2.97. The structural model of the human SET domain (PDB I : 3OOI) allowed us
to observe the interactions of residues p.R1952, p.Y1997, p.R2017, p.N2020, p.N2065 and p. 2021
with the SA [48], which is bound in a pocket for ed by the SET do ain (Figure 5A). S is a
co on co-substrate invol e in ethyl group transfers in a nu ber of biological processes, and
changes in the structural stability due to mutations near the ligand-binding site could affect the
interaction f t e r tei ith the ligand SAM [48]. In order to investigate this possibility,
we generated homology models of the SET domain with the 2 issense utations liste i a le 4
(shown in Figure 5 , labeled as l e). t ti s .I , . 7 , p.R2017Q, p. 2021R, p.C2027R
and p.G2041 ay cause steric clashes ith neighboring a ino aci side chains or ay affect the
water- ediated r [ , ] ith SAM, thus likely affecting the structural stability of
the protein. The activity of four NSD1 mutations p.R1952W, p.R1984Q, p.R2017W and p.Y1997C
in the SET dom in was investigated [56]. For all four mutations, the results showed complete loss
of th protein’s ability to methylate hist ne for all the four mutations, which is in accordance with
the fi dings published for p.R1952W, p.R1984Q, and p.R2017Q [48]. Using SIFT l sis also
analyzed whether these issense utations in the SET do ain ay affect the protein function based
on sequence ho ology and the physical properties of amino acids. is tool calc lates a score for
every substitution and predicts the functional effect. ll SET do ain utations ere predicted to be
non-tolerable and to affect protein function with scores < 0.05 (Table 4).
Genes 2016, 7, 96 13 of 21
Table 4. Summary of the predictions of the bioinformatics tools PolyPhen 2, SPPIDER, SIFT, I-MUTANT 2.0 and PANTHER, with regard to the effect of point mutations
in the NSD1 gene.











p.R1952W Probably damaging 0.999 Non-interacting Intolerant (0.00) 0.18 Increase Stability −3.04478
p.G1955D Probably damaging 1.000 Non-interacting Intolerant (0.00) −1.47 Decrease Stability −7.27103
p.I1962T Possibly damaging 0.934 Non-interacting Intolerant (0.00) −0.95 Decrease Stability −2.82147
p.R1984G Probably damaging 1.000 Non-interacting Intolerant (0.00) −0.93 Decrease Stability −6.53802
p.R1984Q Probably damaging 1.000 Non-interacting Intolerant (0.00) −0.53 Decrease Stability −6.59809
p.Y1997H Probably damaging 1.000 Non-interacting Intolerant (0.00) −0.95 Decrease Stability −3.31488
p.Y1997S Probably damaging 0.999 Non-interacting Intolerant (0.00) −0.70 Decrease Stability −3.43065
p.Y1997C Probably damaging 1.000 Non-interacting Intolerant (0.00) −1.22 Decrease Stability −4.51444
p.R2005Q Probably damaging 1.000 Non-interacting Intolerant (0.01) −1.13 Decrease Stability −1.95697
p.I2007F Probably damaging 1.000 Non-interacting Intolerant (0.00) −1.65 Decrease Stability −2.97211
p.A2009V Probably damaging 1.000 Non-interacting Intolerant (0.00) −1.25 Decrease Stability −2.74529
p.R2017Q Probably damaging 1.000 Non-interacting Intolerant (0.00) −0.27 Decrease Stability −6.4321
p.R2017W Probably damaging 1.000 Non-interacting Intolerant (0.00) 0.02 Increase Stability −8.09732
p.N2020S Probably damaging 1.000 Non-interacting Intolerant (0.00) −0.81 Decrease Stability −6.32023
p.H2021R Probably damaging 1.000 Non-interacting Intolerant (0.01) 0.16 Increase Stability −9.24832
p.C2027R Probably damaging 1.000 Non-interacting Intolerant (0.00) 0.31 Increase Stability −3.94723
p.C2027Y Probably damaging 1.000 Non-interacting Intolerant (0.00) −0.52 Decrease Stability −4.23261
p.W2032L Probably damaging 0.999 Non-interacting Intolerant (0.001) −1.03 Decrease Stability −6.15612
p.R2039C Probably damaging 1.000 Non-interacting Intolerant (0.00) −1.58 Decrease Stability −3.90311
p.G2041D Probably damaging 1.000 Non-interacting Intolerant (0.00) −2.27 Decrease Stability −3.7109
p.T2055I Probably damaging 0.999 Non-interacting Intolerant (0.00) −0.97 Decrease Stability −3.05772
p.Y2058C Probably damaging 1.000 Non-interacting Intolerant (0.00) 0.27 Increase Stability −7.73506
AA: amino acid, DDG: delta delta G/free energy change.
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We further analyzed these mutations using PolyPhen2 [37], which uses information about the
structure of the protein (hydrophobicity, charge effects and charges in molecular contacts) and multiple
sequence alignment to predict the effect of mutations based on the Position Specific Independent Count
Score difference. Based on the calculated alignment score and difference in structural parameters,
PolyPhen2 designated all 22 missense variants as being “probably damaging” with a score of 1 or very
close to it. In order to improve prediction accuracy of structure based tools, we also used the support
vector machine based tool I-Mutant 2.0 [35], which predicts the effect of point mutations on protein
stability. Seventeen missense mutations including p.I2007F are predicted to decrease stability with
negative scores among 22 variants (Table 4). In addition we used SPPIDER [36] analysis to determine
whether sites affected by these mutations are possible binding sites in the NSD1 sequence, as such sites
are likely to affect protein function and signaling. Although SPPIDER did not predict any residue to be
an interaction site (Table 4), I-Mutant 2.0 suggested that these mutations might increase or decrease
the stability of the protein, indicating the deleterious effects of these mutations.
4. Discussion
Because of the phenotypic overlap with other groups of overgrowth syndromes, such as
Weaver, Bannayan–Riley–Ruvalcaba and Beckwith–Wiedemann syndromes, Sotos syndrome may
be challenging to diagnose [8]. Although the presence of the three major criteria and several other
conditions associated with Sotos syndrome allow us to infer a clinical diagnosis of typical Sotos
syndrome, the genetic analysis of the NSD1 gene is considered another criterion for the confirmation of
the molecular diagnosis. NSD1 mutations are found in 70%–93% of classical cases of Sotos syndrome,
but the molecular basis is unknown for remaining patients [11,14,15,57]. In our study, we have
identified 11 different NSD1 mutations including three novel ones in 11 Brazilian Sotos patients. The
prevalence of NSD1 mutations in our Brazilian Sotos patients was lower (32%, 11 out of 34 patients)
compared to the frequency reported for other populations. Although the whole genome microarray
did not identify any large 5q35 microdeletions involving the NSD1 gene in the 23 patients that were
negative by NSD1 sequencing analysis, additional studies such as Multiplex Ligation-dependent
Probe Amplification (MLPA) or targeted high density SNP array need to be performed to rule out the
presence of smaller NSD1 deletions. Therefore, this low prevalence of NSD1 intragenic mutations in
Brazilian Sotos patients is probably due to ethnic differences, a different frequency of the microdeletion,
mutations in non-coding regions or mutations in other genes.
The mutations abrogating NSD1 function include missense mutations, nonsense mutations, small
intragenic insertions/deletions, splicing defects and microdeletions, which are distributed over the
entire gene including both coding and non-coding sequences [1,4,11]. Chromosomal microdeletions
involving the NSD1 gene have been described as a major cause of Sotos syndrome in Japanese patients
(prevalence >45%) [14], but are less frequently found in non-Japanese patients (approximately 10%
of prevalence), where intragenic point mutations are highly prevalent [4,11,57]. The reason for this
discrepancy is not known, but the presence of low-copy repeats (LCRs), highly homologous sequences,
in regions flanking proximal and distal breakpoints of the common deletion suggests that LCRs may
mediate the deletion [14]. A previous study identified one patient with total deletion of NSD1 and two
patients with partial deletion of NSD1 among 30 Brazilian patients with the clinical diagnosis of Sotos
syndrome [58], suggesting that the prevalence of microdeletions involving NSD1 is likely to be low in
Brazilian Sotos patients. Among the 11 patients with 11 different NSD1 mutations in our study, three
patients had NSD1 mutations, including one missense, one nonsense and one-frameshift mutation.
In agreement with previous studies in other populations, the phenotypic characterization of
Brazilian Sotos patients with a mutant NSD1 genotype suggests that the most consistent diagnostic
criterion in Sotos syndrome is represented by facial dysmorphism, in association with a variable
number of additional major criteria [1,11,12,59]. As summarized in Tables 2 and 3, most NSD1 mutant
Sotos patients exhibited a typical facial gestalt including macrocephaly (10/11, 91%), prominent
forehead (11/11, 100%), ocular hypertelorism (11/11, 100%) and pointed chin (11/11, 100%). Other
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frequent features among our patients with intragenic mutations were the presence of hypotonia
(11/11, 100%), excessive growth velocity (10/11, 91%) and delayed learning ability (8/9, 89%).
Advanced bone age, one of the major diagnostic criteria for Sotos syndrome, was not significant
in five patients. In contrast, other criteria including seizures, heart defects and intellectual disability
were inconsistent features, although most patients display delayed developmental milestones. We also
tried to compare phenotypes in our Sotos patients to other reported cases with the same mutations.
Due to the unavailability of the detailed phenotypic information of the reported cases with the same
mutations identified by our study, however, it was not possible to establish a correlation between
clinical features and the type of mutations. More data should be accumulated to explain appropriate
genotype-phenotype correlations and ethnic difference in the prevalence of different NSD1 mutations.
NSD1 contains multiple functional domains including a zinc finger-like PHD domain, a PWWP
motif and a SET domain. In an earlier study, NSD1 had been reported to contain six functional domains
(PHD-1, PHD-2, PHD-3, PWWP-1, PWWP-2 and SET) [22]. However, a recent study proposed the
existence of additional PHD domains (two canonical and one putative) in NSD1 [19]. Therefore, the
number of functional domains in NSD1, especially the PHD domains, has not been clearly defined
yet. Our bioinformatics analyses suggested that NSD1 contains five PHD domains (Table 1, Figure 1B).
However, a putative PHD domain (amino acid positions 2164–2205) reported previously [19] could
not be identified. Other functional domains including two PWWP motifs, one SET domain and one
post-SET domain also appeared present in NSD1, and their locations highly overlap with previous
reports [19,22].
NSD1 is a family member of histone methyltrasferases and regulates the expression of target
genes through the post-translational modification of histones. Thus, disruption of HMTase activity in
NSD1 could have severe phenotypic consequences [60]. Studies have shown that NSD1 methylates on
histone H3 lysine 36 (H3K36), H4 lysine 44 (H4K44) and H1.5 lysine 168 (H1.5K168) [24,61]. NSD1
has also been shown to activate nuclear factor-κB (NF-κB)-p65, a subunit of the NF-κB transcription
complex through K218/K221 methylation. NF-κB is a central coordinator of immune and inflammatory
responses [62]. Furthermore, translocations involving NSD1 have been found in patients with acute
myeloid leukemia (AML) and breast cancer, indicating that NSD1 may function in the regulation of
multiple downstream genes involved in various processes, such as bone morphogenesis, development
and cancer [61,63]. A recent in vitro study showed that PHD domains in NSD1 bind mono-, di- or
tri-methylated histones, H3K4 and H3K9, and point mutations in PHD domains would disrupt the
transcriptional regulation of NSD1 by compromising the binding to these methylated lysines and to
the transcription cofactor Nizp1 [19].
Twenty-one missense mutations have been previously reported in the SET domain [5,11,13,26–29,50]
and one of the novel missense mutations we identified, c.6019A>T (p.I2007F), also occurred at
a highly conserved amino acid in the SET domain (Figure 3). The SET domain is required for
methyltransferase activity in all HMTases that are critical for genetic regulation at the epigenetic
level [64,65]. Several different mechanisms have been proposed, but there has been no consensus
regarding the understanding of the catalytic mechanism upon the transfer of the methyl group by the
SET domain. However, the recently determined three-dimensional structures of the SET domains from
chromosomal proteins support the notion that SAM and the lysine residue of the substrate histone
tail must first be bound with a proper orientation in the catalytic pocket of the SET domain. Then,
methyl transfer from SAM to the ε-amino of the target lysine likely proceeds by a direct in-line SN2
nucleophilic attack through a nearby tyrosine residue [66–68]. Several different bioinformatics analyses
suggested that all 22 missense mutations in the SET domain would have deleterious effects, which
may be induced by changes in the functional activity of this domain, by changing protein stability or
by interfering with the ability to bind to a ligand, among other factors. These data are in agreement
with published results [48,56]. Specifically, we have investigated p.I2007F, where the side chain of
phenylalanine is significantly larger than that of isoleucine, pushing neighboring side chains outwards,
possibly into the binding pocket. As a result, the ligand may either completely or partially lose its
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affinity with the protein, which would correspond to a significant loss-of-function of this domain.
This computational result has yet to be confirmed by experimental data. However, SIFT analysis
suggested that this mutation would affect the protein function, supported by molecular dynamics
simulation results which revealed that it would significantly reduce the size of the binding pocket that
strongly affects ligand-binding properties. This result is consistent with the previous observation
that the Sotos mutation involving five arginine residues in the SET domain had greatly reduced
H3K36 methyltransferase activities in vitro; some of them showed almost undetectable enzymatic
activities [48]. Therefore, it may have significant deleterious effects on the methyltransferase activity of
NSD1 resulting in altered gene expression patterns by the deregulation of histone modifications at
H3K36 and H4K44 [48]. Moreover, uncontrolled gene expression resulting from mutations in genes
encoding histone modifiers including histone acetyltransferases, deacetylases, methyltransferases and
kinases causes developmental defects, in particular those involving the heart and nervous system,
as well as cancers [69–71]. In fact, some types of human congenital diseases have been shown to
involve the abnormal expression or activity of a family of histone methyltransferases. These include
NSD2/ Wolf-Hirschhorn Syndrome Candidate 1 (WHSC1) in Wolf-Hirschhorn syndrome, NSD3 in
cancer, euchromatin histone methyl transferase1 (EHMT1) in the 9q subtelomeric deletion syndrome
and enhancer of zeste, drosophilahomolog 2 (EZH2) in Weaver syndrome [72–75]. More recently,
mutations DNMT3A, another DNA methyltransferase involved in the de novo methylation of DNA
were also identified in patients with overgrowth syndromes [76]. Our data combined with two
previous published data sets [48] suggest that point mutations in the NSD1 SET domain disrupt
its transcriptional activity by interfering with its ability to bind a ligand required for methyl group
transfer and by changing protein stability. Therefore, highly conserved amino acids in the SET domain
are critical for the transcriptional activity of NSD1 required for the regulation of gene expression of a
number of downstream targets. Abrogation of this NSD1 transcriptional regulation would result in
the multiple phenotypes observed in Sotos patients.
NSD1 was reported to be expressed strongly in fetal brain, kidney, skeletal muscle, spleen
and the thymus in Northern blot analysis [22]. However, little is known about its expression in
various brain regions. Using RT-qPCR, we examined the NSD1 expression pattern in human brain,
fetal brain, and additional 11 CNS human tissues compared to lymphocyte (Figure 2). Among the
tissues examined, fetal brain displayed the highest NSD1 expression, suggesting a fetal onset of the
neurological phenotype of this congenital disorder. It also showed high expression in cerebellum,
which is commensurate with the hypoplasia of cerebellar vermis in Sotos syndrome [13].
Since NSD1 mutations have not been detected in 7%–30% of Sotos patients, other genes were also
screened in some cases of unexplained Sotos syndrome. Because of their high sequence similarities
with NSD1, both the NSD2 and NSD3 genes were tested previously as potential candidates for
NSD1-negative Sotos syndrome cases [77]. However, no deletions were identified in 78 overgrowth
syndrome cases without NSD1-mutation. Two missense alterations in NSD2 were identified in two
non-Sotos overgrowth cases but neither was within a functional domain [77]. This group also identified
three synonymous and two intronic variants in NSD2 and two synonymous substitutions in NSD3.
Intragenic deletion of glypican 3 (GPC3) involved in Simpson–Golabi–Behmel syndrome was identified
in a patient who was originally diagnosed with Sotos syndrome [78,79], and two 11p15 anomalies
including paternal uniparental disomy and epigenetic defects (abnormal methylation status) were also
identified among 20 patients with Sotos syndrome [80]. However, the molecular defect underlying a
significant proportion of sporadic Sotos cases still remains unknown. In particular, in our Brazilian
Sotos cohort, 68% of Sotos syndrome patients represented in 23 families have an unknown etiology.
Therefore, these NSD1 mutation-negative families will surely contribute to the identification of new
genes involved in Sotos syndrome in the future.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/7/11/96/s1.
Table S1: PCR primers used for NSD1 mutational analysis. Table S2: Primers used for RT-qPCR. Table S3:
SNPs of NSD1 found in our 34 Sotos patients.
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